Skip to Content

'
Deborah A. Kuban, M.D., F.A.C.R., F.A.S.T.R.O.

Present Title & Affiliation

Primary Appointment

Professor, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Executive Director, Cancer Network, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Deputy Division Head, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 1202
Houston, TX 77030
Room Number: ACB P1.2864

Education & Training

Degree-Granting Education

1981 Medical College of Georgia, Augusta, GA, MD, Medicine
1977 Valdosta State College, Valdosta, GA, BS, Summa Cum Laude, Biology

Postgraduate Training

6/1982-6/1985 Residency, Radiation Oncology, Eastern Virginia Graduate School of Medicine, Norfolk, VA
6/1981-6/1982 Internship, General Surgery, Eastern Virginia Graduate School of Medicine, Norfolk, VA

Board Certifications

1986 Therapeutic Radiology, American Board of Radiology
1981 Diplomat, National Board of Medical Examiners

Experience/Service

Administrative Appointments/Responsibilities

Medical Director, Genitourinary Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2011-present
Medical Director, M. D. Anderson Physicians Network, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2009-present
Medical Director, Patient Affairs, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2007-present
Faculty Host Advocate, The University of Texas MD Anderson Cancer Center Physicians Network, Houston, TX, 1/2006-present
Medical Director, Multi-disciplinary Prostate Cancer Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, 3/2004-present
Genitourinary Section Chief, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2001-present

Consultantships

Scientific Advisory Board, BioTheranostics, San Diego, CA, 2/2011-1/2012
Scientific Advisory Board Member, Ferring Pharmaceuticals, Newtown Square, PA, 9/2009-8/2010

Institutional Committee Activities

Member, Physician Relations Faculty Advisory Board, 2012-present
Member, Global Academic Programs Steering Committee, 2012-2014
Member, National Clinical Expansion Steering Committee, 2012-2014
Member, Banner MD Anderson Relationship Committee, 2011-present
Member, Regional Cancer Center Strategic Committee, 2011-2012
Member, Committee on Faculty Awards, 2011-2012
Member, MD Anderson Physicians Network Annual Symposium Planning Committee, 2010-present
Member, Clinical Effectiveness Subcommittee of the Medical Practice Committee, Working Group on Prostate, Bladder and Testicular Cancer., 2008-present
Member, Genitourinary Center Survivorship Committee, 2008-present
Member, Radiation Oncology Divisional Recruitment Committee, 2007-present
Member, Radiation Oncology Promotion and Tenure Committee, 2007-present
Member, Physicians Network Credentials Committee, 2006-present
Member, Division Leadership Committee, Radiation Oncology Department, 2003-present
Member, Genitourinary Center Steering Committee, 2001-2010

Honors and Awards

2014 America's Top Doctors, Castle Colony Guide
2013 Golden Finger Award, Best Presentation, Sun, Sand & Seeds Conference Boca Raton, FL
2008-2013 Best Doctors in America: Texas
2008 International Who's Who of Professional & Business Women, The American Biographical Institute
2007 Fellow, American Society for Therapeutic Radiology and Oncology
2007 Leading Health Professionals of the World, Cambridge, England
2006 Fellow, American College of Radiology
2003 Faculty of 1000 in Medicine, Philadelphia, PA
2003 The Global Directory of Who's Who, New York, NY
2002 Houston's Best Doctors, Inside Houston Magazine
2002 Houston's Best Women Doctors, Inside Houston Magazine
1992 Listed among the Best Cancer Specialists in the U.S., Radiation Oncology, Genitourinary, Good Housekeeping Magazine

Professional Memberships

American Board of Radiology
Oral Board Examiner, 1994-present
American Society for Radiation Oncology
Chair, Corporate Relations Committee of the Board of Directors, 2009-present
Member, Research Council Evidence-based clinical practice guideline: Role of post-operative radiotherapy for radical prostatectomy panel, 2007-2011
American Society of Clinical Oncology
Member, Roster of Cancer Experts, 2005-present
N.C.I. Cancer Therapy Evaluation Program (CTEP)
Co-Chair, Prostate Cancer Task Force of The G.U. Steering Committee, 2009-present
National Comprehensive Cancer Network
Member, Bladder Cancer Guidelines Panel, 2007-present
Quality Research in Radiation Oncology Committee (QRRO)
Member, 2007-present
Radiation Oncology Institute
Nominating Committee Member, 2011-present
Vice President, 2011-present
Board of Trustees Member, 2009-present
Campaign Cabinet Member, 2008-present
Radiation Therapy Oncology Group
Member, Genitourinary Committee, 2001-present
Texas Medical Society
Member, 2008-present
U.S. Department of Defense Prostate Cancer Research Program, Frederick, MD
Integration Panel Member, 1/2012-4/2014

Selected Publications

Peer-Reviewed Original Research Articles

1. Rosenthal SA, Hunt D, Sartor AO, Pienta KJ, Gomella L, Grignon D, Rajan R, Kerlin KJ, Jones CU, Dobelbower M, Shipley WU, Zeitzer K, Hamstra DA, Donavanik V, Rotman M, Hartford AC, Michalski J, Seider M, Kim H, Kuban DA, Moughan J, Sandler H. A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. Int J Radiat Oncol Biol Phys. e-Pub 7/21/2015. PMID: 26209502.
2. Ludwig MS, Kuban DA, Strom SS, Du XL, Lopez DS, Yamal JM. Assessing the Optimum Use of Androgen-Deprivation Therapy in High-Risk Prostate Cancer Patients Undergoing External Beam Radiation Therapy. Am J Mens Health. e-Pub 4/19/2015. PMID: 25891393.
3. Parker PA, Davis JW, Latini DM, Baum G, Wang X, Ward JF, Kuban D, Frank SJ, Lee AK, Logothetis CJ, Kim J. The Relationship Between Illness Uncertainty, Anxiety, Fear of Progression, and Quality of Life in Men With Favorable Risk Prostate Cancer Undergoing Active Surveillance. BJU Int. e-Pub 2/24/2015. PMID: 25714186.
4. Skolarus TA, Dunn RL, Sanda MG, Chang P, Greenfield TK, Litwin MS, Wei JT, PROSTQA Consortium, PROSTQA Consortium. Minimally important difference for the expanded prostate cancer index composite short form. Urology 85(1):101-6, 1/2015. PMCID: PMC4274392.
5. Ludwig MS, Kuban DA, Strom SS, Du XL, Lopez DS, Yamal JM. The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: effects of radiation dose escalation. BMC Cancer 15:190, 2015. e-Pub 3/27/2015. PMCID: PMC4472156.
6. Bian SX, Kuban DA, Levy LB, Oh J, Choi S, McGuire SE, Frank SJ, Mahmood U, Nguyen PL, Pugh TJ, Lee AK, Hoffman KE. The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer. Am J Clin Oncol. e-Pub 4/11/2014. PMID: 24732810.
7. Volk RJ, McFall SL, Cantor SB, Byrd TL, Le YC, Kuban DA, Mullen PD. 'It's not like you just had a heart attack': decision-making about active surveillance by men with localized prostate cancer. Psychooncology 23(4):467-72, 4/2014. e-Pub 11/14/2013. PMCID: PMC3983844.
8. Mahmood U, Levy LB, Nguyen PL, Lee AK, Kuban DA, Hoffman KE. Current Clinical Presentation and Treatment of Localized Prostate Cancer in the United States. J Urol 192(6):1650-6, 2014. PMID: 24931803.
9. Mahmood U, Pugh T, Frank S, Levy L, Walker G, Haque W, Koshy M, Graber W, Swanson D, Hoffman K, Kuban D, Lee A. Declining use of brachytherapy for the treatment of prostate cancer. Brachytherapy 13(2):157-162, 2014. PMID: 24050892.
10. Thaker NG, Kudchadker RJ, Swanson DA, Albert JM, Mahmood U, Pugh TJ, Boehling NS, Bruno TL, Prestidge BR, Crook JM, Cox BW, Potters L, Moran BJ, Keyes M, Kuban DA, Frank SJ. Establishing High-Quality Prostate Brachytherapy Using a Phantom Simulator Training Program. Int J Radiat Oncol Biol Phys 90(3):579-86, 2014. PMID: 25151539.
11. Madsen LT, Kuban DA, Choi S, Davis JW, Kim J, Lee AK, Domain D, Levy L, Pisters LL, Pettaway CA, Ward JF, Logothetis C, Hoffman KE. Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic. J Natl Compr Canc Netw 12(7):993-8, 2014. PMID: 24994920.
12. Wang J, Kudchadker R, Choi S, Pettaway CA, Choi H, Hobbs BD, Occena MC, McGuire SE, Pugh TJ, Hoffman K, Mahmood U, Kuban DA. Local recurrence map to guide target volume delineation after radical prostatectomy. Pract Radiat Oncol 4(6):e239-46, 2014. e-Pub 4/16/2014. PMID: 25407875.
13. Hoffman KE, Niu J, Shen Y, Jiang J, Davis JW, Kim J, Kuban DA, Perkins GH, Shah JB, Smith GL, Volk RJ, Buchholz TA, Giordano SH, Smith BD. Physician Variation in Management of Low-Risk Prostate Cancer: A Population-Based Cohort Study. JAMA Intern Med 174(9):1450-9, 2014. PMID: 25023650.
14. Bilen MA, Hariri H, Leon C, Guo CC, Kuban DA, Pisters LL, Tu SM. Positive FDG-PET/CT Scans of a Residual Seminoma After Chemotherapy and Radiotherapy: Case Report and Review of the Literature. Clin Genitourin Cancer 12(4):147-50, 2014. PMID: 24674785.
15. Ballo MT, Chronowski GM, Schlembach PJ, Bloom ES, Arzu IY, Kuban DA. Prospective Peer Review Quality Assurance for Outpatient Radiation Therapy. Pract Radiat Oncol 4(5):279-84, 2014. PMID: 25194094.
16. Hoffman KE, Voong KR, Pugh TJ, Skinner H, Levy LB, Takiar V, Choi S, Du W, Frank SJ, Johnson J, Kanke J, Kudchadker RJ, Lee AK, Mahmood U, McGuire SE, Kuban DA. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys 88(5):1074-84, 2014. PMID: 24661661.
17. Nguyen QN, Levy LB, Lee AK, Choi SS, Frank SJ, Pugh TJ, McGuire S, Hoffman K, Kuban DA. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer 119(18):3265-71, 9/15/2013. e-Pub 6/24/2013. PMID: 23798338.
18. Li X, Quan EM, Li Y, Pan X, Zhou Y, Wang X, Du W, Kudchadker RJ, Johnson JL, Kuban DA, Lee AK, Zhang X. A Fully Automated Method for CT-on-Rails-Guided Online Adaptive Planning for Prostate Cancer Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys 86(5):835-41, 2013. PMID: 23726001.
19. Melancon AD, Lee AK, Kudchadker R, Zhang L, Tucker SL, Kuban D, Dong L. Anatomic variation and dosimetric consequences of neoadjuvant hormone therapy before radiation therapy for prostate cancer. Pract Radiat Oncol 3(4):329-36, 2013. PMID: 24674406.
20. Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Bladder cancer. J Natl Compr Canc Netw 11(4):446-75, 2013. PMID: 23584347.
21. Pair ML, Du W, Rojas HD, Kanke JE, McGuire SE, Lee AK, Kuban DA, Kudchadker RJ. Dosimetric effects of weight loss or gain during volumetric modulated arc therapy and intensity-modulated radiation therapy for prostate cancer. Med Dosim 38(3):251-4, 2013. PMID: 23540491.
22. Pugh TJ, Frank SJ, Achim M, Kuban DA, Lee AK, Hoffman KE, McGuire SE, Swanson DA, Kudchadker R, Davis JW. Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: Implications for prostate brachytherapy. Brachytherapy 12(3):204-9, 2013. PMID: 22673704.
23. Cerne JZ, McGuire SE, Grant SR, Munsell MF, Lee AK, Kudchadker RJ, Choi SL, Mahmood U, Hoffman KE, Pugh TJ, Frank SJ, Kuban DA. Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients. Prostate Cancer Prostatic Dis 16(4):346-51, 2013. PMID: 23939133.
24. Castle KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, Pugh TJ, McGuire SE, Kuban DA. Is Androgen Deprivation Therapy Necessary in All Intermediate-Risk Prostate Cancer Patients Treated in the Dose Escalation Era? Int J Radiat Oncol Biol Phys 85(3):693-9, 2013. PMID: 22836052.
25. Hamstra DA, Conlon AS, Daignault S, Dunn RL, Sandler HM, Hembroff AL, Zietman AL, Kaplan I, Ciezki J, Kuban DA, Wei JT, Sanda MG, Michalski JM, PROSTQA Consortium Study Group. Multi-institutional Prospective Evaluation of Bowel Quality of Life After Prostate External Beam Radiation Therapy Identifies Patient and Treatment Factors Associated With Patient-Reported Outcomes: The PROSTQA Experience. Int J Radiat Oncol Biol Phys 86(3):546-53, 2013. PMID: 23561651.
26. Gay HA, Michalski JM, Hamstra DA, Wei JT, Dunn RL, Klein EA, Sandler HM, Saigal C, Litwin M, Kuban D, Hembroff L, Chang P, Sanda MG, PROSTQA Consortium. Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study. Urology 82(6):1363-9, 2013. PMID: 24139340.
27. Beard CJ, Travis LB, Chen MH, Arvold ND, Nguyen PL, Martin NE, Kuban DA, Ng AK, Hoffman KE. Outcomes in stage I testicular seminoma: A population-based study of 9193 patients. Cancer 119(15):2271-7, 2013. PMID: 23633409.
28. Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Penile Cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 11(5):594-615, 2013. PMID: 23667209.
29. Kazer MW, Bailey DE Jr, Chipman J, Psutka SP, Hardy J, Hembroff L, Regan M, Dunn RL, Crociani C, Sanda MG, [Kuban DA]. PROST QA Consortium Study Group. BJU Int 111(3 pt B):E84-91, 2013.
30. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. J Urol 189(1 Suppl):S2-S11, 2013. PMID: 23234625.
31. McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA. PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era. Int J Radiat Oncol Biol Phys 85(1):e39-46, 2013. PMID: 23102837.
32. Pugh TJ, Munsell MF, Choi S, Nguyen QN, Mathai B, Zhu XR, Sahoo N, Gillin M, Johnson JL, Amos RA, Dong L, Mahmood U, Kuban DA, Frank SJ, Hoffman KE, McGuire SE, Lee AK. Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 87(5):946-53, 2013. PMID: 24139077.
33. Corn PG, Song DY, Heath E, Maier J, Meyn R, Kuban D, DePetrillo TA, Matthew P. Sunitinib Plus Androgen Deprivation and Radiation Therapy for Patients With Localized High-Risk Prostate Cancer. Results from a Multi-Institutional Phase I Study. Int J Radiat Oncol Biol Phys 86(3):540-5, 2013.
34. Bian SX, Kuban DA, Levy LB, Oh J, Castle KO, Pugh TJ, Choi S, McGuire SE, Nguyen QN, Frank SJ, Nguyen PL, Lee AK, Hoffman KE. Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol 9(9):2346-52, 9/2012. e-Pub 2/21/2012. PMID: 22357249.
35. Quan EM, Li X, Li Y, Wang X, Kudchadker RJ, Johnson JL, Kuban DA, Lee AK, Zhang X. A Comprehensive Comparison of IMRT and VMAT Plan Quality for Prostate Cancer Treatment. Int J Radiat Oncol Biol Phys 83(4):1169-78, 2012. PMID: 22704703.
36. Vassiliev ON, Kudchadker RJ, Kuban DA, Frank SJ, Choi S, Nguyen QN, Lee AK. Dosimetric impact of fiducial markers in patients undergoing photon beam radiation therapy. Phys Med 28(3):240-4, 2012. PMID: 21875820.
37. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J 18(1):1-8, 2012. PMID: 22290249.
38. Fisher CM, Troncoso P, Swanson DA, Munsell MF, Kuban DA, Lee AK, Yeh SF, Frank SJ. Knife or needles? A cohort analysis of outcomes after radical prostatectomy or brachytherapy for men with low- or intermediate-risk adenocarcinoma of the prostate. Brachytherapy 11(6):429-34, 2012. PMID: 22727472.
39. Brooks C, Sheu T, Bridges K, Mason K, Kuban D, Mathew P, Meyn R. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer. Radiat Oncol 7(1):154, 2012. PMID: 22967802.
40. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Prostate cancer-specific mortality after definitive radiation therapy: Who dies of disease? Eur J Cancer 48(11):1664-71, 2012. PMID: 22336663.
41. Sharp HJ, Swanson DA, Pugh TJ, Zhang M, Phan J, Kudchadker R, Bruno TL, Kuban DA, Lee AK, Choi S, Nguyen QN, Hoffman KE, McGuire SE, Frank SJ. Screening Colonoscopy Before Prostate Cancer Treatment Can Detect Colorectal Cancers in Asymptomatic Patients and Reduce the Rate of Complications After Brachytherapy. PRO 2(3):e7, 2012.
42. Boonsirikamchai P, Kaur H, Kuban DA, Jackson E, Hou P, Choi H. Use of maximum slope images generated from dynamic contrast-enhanced MRI to detect locally recurrent prostate carcinoma after prostatectomy: a practical approach. AJR Am J Roentgenol 198(3):W228-36, 2012. PMID: 22358019.
43. Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, Pollack A. Long-term Failure Patterns and Survival in a Randomized Dose-Escalation Trial for Prostate Cancer. Who Dies of Disease? Int J Radiat Oncol Biol Phys 79(5):1310-7, 2011. PMID: 20493642.
44. Samuelian JM, Swanson DA, Kudchadker RJ, Pugh TJ, Kuban DA, Lee AK, Choi S, Nguyen QN, Bruno TL, Frank SJ. Long-term tumor control after brachytherapy for base-of-prostate cancer. J Contemp Brachytherapy 3(4):183-7, 2011. PMID: 23346126.
45. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG. Prediction of erectile function following treatment for prostate cancer. JAMA 306(11):1205-14, 2011. PMID: 21934053.
46. Hoffman KE, Nguyen PL, Chen MH, Chen RC, Choueiri TK, Hu JC, Kuban DA, D'Amico AV. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol 185(1):116-20, 2011. PMID: 21074194.
47. Iyengar P, Levy LB, Choi S, Lee AK, Kuban DA. Toxicity Associated With Postoperative Radiation Therapy for Prostate Cancer. Am J Clin Oncol 34(6):611-8, 2011. PMID: 21150565.
48. Frank SJ, Kudchadker RJ, Kuban DA, De Crevoisier R, Lee AK, Cheung RM, Choi S, Tucker SL, Dong L. A Volumetric Trend Analysis of the Prostate and Seminal Vesicles During a Course of Intensity-Modulated Radiation Therapy. Am J Clin Oncol 33(2):173-5, 2010. PMID: 20010077.
49. Tucker SL, Dong L, Bosch WR, Michalski J, Winter K, Mohan R, Purdy JA, Kuban D, Lee AK, Cheung MR, Thames HD, Cox JD. Late Rectal Toxicity on RTOG 94-06: Analysis Using a Mixture Lyman Model. Int J Radiat Oncol Biol Phys 78(4):1253-60, 2010.
50. Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol 96(1):6-12, 2010. PMID: 20400191.
51. Archambault L, Briere TM, Pönisch F, Beaulieu L, Kuban DA, Lee A, Beddar S. Toward a Real-Time In Vivo Dosimetry System Using Plastic Scintillation Detectors. Int J Radiat Oncol Biol Phys 78(1):280-7, 2010.
52. Madsen LT, Craig C, Kuban D. A multidisciplinary prostate cancer clinic for newly diagnosed patients: developing the role of the advanced practice nurse. Clin J Oncol Nurs 13(3):305-9, 2009. PMID: 19502188.
53. Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar KS, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG, Wilson TG. Bladder cancer. J Natl Compr Canc Netw 7(1):8-39, 2009. PMID: 19176203.
54. Tu SM, Lopez A, Leibovici D, Bilen M, Evliyaoglu F, General RD, Aparicio A, Pagliaro LC, Guo CC, Kuban DA, Johnson MM, Logothetis CJ, Lin SH, Pisters LL. Ductal Adenocarcinoma of the Prostate - Clinical Features and Implications After Local Therapy. Cancer 115(13):2872-80, 2009. PMID: 19402048.
55. Cox JD, Giralt SA, Veazie ML, Ajani JA, Bruner JM, Chan KW, Hittelman WN, Hunt KK, Iyer RB, Karp DD, Kuban DA, Lippman SM, Raad II, Rodriguez-Bigas MA, Zwelling LA, Markman M. Evaluating Quality in Clinical Cancer Research: The M.D. Anderson Cancer Center Experience. Oncology 77(2):75-81, 2009. PMID: 19571599.
56. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. J Urol 182(5):2232-41, 2009. PMID: 19781717.
57. Frank SJ, Levy LB, Kuban DA, Lee AK, Kudchadker RJ, Bruno TL, Vulpen MV, Swanson DA. Prostogram Predicted Brachytherapy Outcomes are Not Universally Accurate: An Analysis Based on the M. D. Anderson Cancer Center Experience With (125)Iodine Brachytherapy. J Urol 181(4):1658-63, 2009. PMID: 19233434.
58. Williams BJ, Fox BD, Sciubba DM, Suki D, Tu SM, Kuban D, Gokaslan ZL, Rhines LD, Rao G. Surgical management of prostate cancer metastatic to the spine. J Neurosurg Spine 10(5):414-22, 2009. PMID: 19442002.
59. Anderson JF, Swanson DA, Levy LB, Kuban DA, Lee AK, Kudchadker R, Phan J, Bruno T, Frank SJ. Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experience. Urology 74(3):601-5, 2009. PMID: 19589580.
60. Lawton C, Michalski J, El-Naqa I, Kuban D, Lee W, Rosenthal S, Zietman A, Sandler H, Shipley W, Ritter M, Valicenti R, Cattan C, Roach M, Pisansky T, Seider M.. Variation in the Definition of Clinical Target Volumes for Pelvic Nodal Conformal Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 74(2):377-82, 2009. PMID: 18947941.
61. Trabulsi EJ, Valicenti RK, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton CN, Muchalski JM, Zefelsky MJ, Kupelian PA, Lin DW, Anscher MS, Slawin KM, Roehrborn CG, Forman JD, Liauw SL, Kestin L, Deweese TL. Scardino PT, Stephenson AJ, Pollack A. A Multi-Institutional Matched-Control Analysis of Adjuvant and Salvage Postoperative Radiation Therapy for pT3-4N0 Prostate Cancer. Urology 72(6):1298-302, 2008. PMID: 18672274.
62. O'Daniel, Dong L, Zhang J, Wang C, Tucker S, Kudchadker R, Lee AK, Cheung MR, Cox J, Kuban D, Mohan R. Daily bone alignment with limited repeat CT correction rivals daily ultrasound alignment for prostate radiotherapy. Int J Radiat Oncol Biol Phys 71(1):274-280, 2008.
63. Kudchadker RJ, Swanson DA, Kuban DA, Lee AK, Bruno TL, Frank SJ. Is a Loose-Seed Nomogram Still Valid for Prostate Brachytherapy in a Stranded-Seed Era? Int J Radiat Oncol Biol Phys. 72(2):623-7, 2008. PMID: 18410998.
64. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67-74, 2008. PMID: 17765406.
65. Wang H, Garden AS, Zhang L, Wei X, Ahamad A, Kuban DA, Komaki R, O'Daniel J, Zhang Y, Mohan R, Dong L. Performance evaluation of automatic anatomy segmentation algorithm on repeat or four-dimensional computed tomography images using deformable image registration method. Int J Radiat Oncol Biol Phys 72(1):210-9, 2008. PMID: 18722272.
66. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358(12):1250-61, 2008. PMID: 18354103.
67. Frank SJ, Dong L, Kudchadker RJ, De Crevoisier R, Lee AK, Cheung R, Choi S, O'Daniel J, Tucker SL, Wang H, Kuban DA. Quantification of prostate and seminal vesicle interfraction variation during IMRT. Int J Radiat Oncol Biol Phys 71(3):813-20, 2008. PMID: 18207664.
68. Frank SJ, Pisters LL, Davis J, Lee AK, Bassett R, Kuban DA. An assessment of quality of life following radical prostatectomy, high-dose external beam radiation therapy, and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol 177(6):2151-6, 2007. PMID: 17509305.
69. de Crevoisier R, Melancon AD, Kuban DA, Lee AK, Cheung RM, Tucker SL, Kudchadker RJ, Newhauser WD, Zhang L, Mohan R, Dong L. Changes in the Pelvic Anatomy After an IMRT Treatment Fraction of Prostate Cancer. Int J Radiat Oncol Biol Phys 68(5):1529-36, 2007. PMID: 17544595.
70. Zhang X, Dong L, Lee AK, Cox JD, Kuban DA, Zhu RX, Wang X, Li Y, Newhauser WD, Gillin M, Mohan R. Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment. Int J Radiat Oncol Biol Phys 67(2):620-9, 2007. PMID: 17236979.
71. Frank SJ, Grimm PD, Sylvester JE, Merrick GS, Davis BJ, Zietman A, Moran BJ, Beyer DC, Roach M, Clarke DH, Stock RG, Robert Lee W, Michalski JM, Wallner KE, Hurwitz M, Potters L, Kuban DA, Prestidge BR, Vera R, Hathaway S, Blasko JC. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States. Brachytherapy 6(1):2-8, 2007. PMID: 17284379.
72. Cheung MR, Tucker SL, Dong L, de Crevoisier R, Lee AK, Frank S, Kudchadker RJ, Thames H, Mohan R, Kuban D. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 67(4):1059-65, 2007. PMID: 17241755.
73. Melancon AD, O'Daniel JC, Zhang L, Kudchadker RJ, Kuban DA, Lee AK, Cheung RM, de Crevoisier R, Tucker SL, Newhauser WD, Mohan R, Dong L. Is a 3-mm intrafractional margin sufficient for daily image-guided intensity-modulated radiation therapy of prostate cancer? Radiother Oncol 85(2):251-259, 2007. PMID: 17892900.
74. Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67:327-33, 2007. PMID: 17084558.
75. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. Am J Clin Oncol 25(15):2035-41, 2007. PMID: 17513807.
76. Feng M, Hanlon AL, Pisansky TM, Kuban D, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Pollack A, Kestin LL, Valicenti RK, Deweese TL, Sandler HM. Predictive Factors for late Genitourinary and Gastrointestinal Toxicity in Patients With Prostate Cancer Treated With Adjuvant or Salvage Radiotherapy. Int J Radiat Oncol Biol Phys 68(5):1417-23, 2007. PMID: 17418972.
77. Vance W, Tucker SL, de Crevoisier R, Kuban DA, Cheung MR. The predictive value of 2-year posttreatment biopsy after prostate cancer radiotherapy for eventual biochemical outcome. Int J Radiat Oncol Biol Phys 67(3):828-33, 2007. PMID: 17161554.
78. Vassiliev ON, Kry SF, Kuban DA, Salehpour M, Mohan R, Titt U. Treatment-planning study of prostate cancer intensity-modulated radiotherapy with a Varian Clinac operated without a flattening filter. Int J Radiat Oncol Biol Phys 68(5):1567-71, 2007. PMID: 17544596.
79. Kry SF, Followill D, White RA, Stovall M, Kuban DA, Salehpour M. Uncertainty of calculated risk estimates for secondary malignancies after radiotherapy. Int J Radiat Oncol Biol Phys 68(4):1265-71, 2007. PMID: 17637398.

Invited Articles

1. Bellmunt J, Attard G, Bahl A, Huland H, Klotz L, Kuban D, Oudard S, Watson W. Advances in the management of high-risk localised and metastatic prostate cancer. BJU Int 109(Suppl 2):8-13, 2012. PMID: 22257099.
2. Carducci MA, Montie JE, Kuban DA. Perspectives on the Management of Localized Prostate Cancer. American Society of Clinical Oncology, Educational Book, 2009.

Editorials

1. Hoffman KE, Kuban DA. Lymph node-positive prostate cancer: the benefit of local therapy. Oncology (Williston Park) 27(7):655, 660-1, 2013. PMID: 23977760.
2. Kuban DA. Localized prostate cancer: the battle of treatment options enters the larger arena. Oncology (Williston Park) 23(10):867, 873, 2009. PMID: 19839428.
3. Kuban DA, Pagliaro L. Salvage Radiotherapy or Observation After Radical Prostatectomy in the PSA era. The American Journal of Hematology/Oncology. 8(3):136-138, 2009.
4. Kuban DA. Reconsidering the case for brachytherapy plus EBRT in high-risk prostate cancer. Oncology 22:1006-1012, 2008.
Other Articles
1. Kuban DA. Book Review of Image-Guided Radiation Therapy of Prostate Cancer. Int J Rad Oncol Biol Phys, 2008.

Abstracts

1. Mahmood U, Walker GV, Levy L, Pugh TJ, McGuire SE, Choi S, Frank SJ, Lee AK, Kuban DA, Hoffman KE. Impact of insurance status on treatment selection for localized prostate cancer in the United States. Int J Radiat Oncol Biol Phys 90(1S):S582, 2014.

Book Chapters

1. Patterson ML, Davis JW, Kim J, Hoffman KE, Osai WE, Kuban DA. Genitourinary Cancer Survivorship Management. In: Advances in Cancer Survivorship Management. Ed(s) Foxhall LE, Rodriguez MA. Springer: New York, NY, 95-104, 2014.
2. Kundra V, Martin S, Kuban D. Prostate Cancer. In: Oncologic Imaging: A Multidisciplinary Approach. Ed(s) Silverman P. Elsevier - Saunders: Philadelphia, PA, 377 - 402, 2012.
3. Kuban DA, Trad ML, Contributors. In: Radiation Therapy Study Guide and Exam Review. Mosby, Inc. St. Louis, MO, 2011.
4. Michalski J, Potters L, Lawton CA, Pisansky TM, Kuban DA. Prostate Cancer. In: Clinical Radiation Oncology. Third Edition. Ed(s) D Meloni, MB Murphy, J Patterson, MG Stueck, L Forgione. Churchill Livingston, an imprint of Elsevier, Inc. Philadelphia, PA, 1037 - 1097, 2011.
5. Logothetis CJ, Troncoso P, Kim J, Davis JW, Kuban DA, Mathew P, Aparicio A. Neoplasms of the Prostate. In: Cancer Medicine 8th Edition. PMPH-USA: Shelton, CT, 1228 - 1254, 2010.
6. Kuban DA, Trad ML. Male Reproductive and Genitourinary Tumors. In: Principles and Practice of Radiation Therapy. Mosby, Inc. St. Louis, MO, 823 - 865, 2009.
7. Kuban DA, Cheung R, Meistrich ML, Hussey DH. The Testicle. In: Radiation Oncology: Rationale, Technique, Results. Mosby, Inc. St. Louis, MO, 653 - 675, 2009.
8. Kuban DA, Potters L, Lawton CA, Pisansky TM. Prostate Cancer. In: Clinical Radiation Oncology. Churchill Livingston an imprint of Elsevier, Inc. Philadelphia, PA, 1165 - 1236, 2007.

Letters to the Editor

1. Kuban DA. In reply to Drs. Schulz and Kagan. Int J Radiat Oncol Biol Phys. 71(4):1288, 2008.

Manuals, Teaching Aids, Other Teaching Publications

1. Volk R, Pettaway C, Kuban D. Knowing Your Options: A Decision Aid for Men with Clinically Localized Prostate Cancer. A Patient Decision Aid Released by AHRQ, http://www.effectivenesshealthcare.ahrq.gov/ehc/decisionaids/prostate-cancer/?EC=MDA, 2011.
2. Kuban DA,. Multidisciplinary Prostate Cancer Clinic. A Guide to Treatment Options. Ed(s) Kuban DA., 2008.
3. Kuban DA. Genitourinary Radiation Guide. U. T. M. D. Anderson Cancer Center, Dept of Radiation Oncology, 2003.
 

Other

1. The University of Texas M.D. Anderson Website. "Genitourinary Radiation Guide", 2003.
2. The University of Texas M.D. Anderson Website. Production and Editing Video - "How to Treat Cancer", 2004-2005.
3. Consultant for Genitourinary Center Website. Prostate Cancer, Kidney Cancer, Bladder Cancer, and Testicular Cancer, 2004-2005.
4. Participant in video. Prostate Cancer, supported by Texas Health Council, 2004-2005.
5. Author. Development and update of M. D. Anderson Clinical Guidelines for Prostate, Bladder and Renal Cancer, 2001 - present.
6. The University of Texas M.D. Anderson Website. Multidisciplinary Prostate Cancer Clinic, 2008.
7. The University of Texas M.D. Anderson Website. Advances in the Treatment of Prostate Cancer. Patient Power, Weekly Web-based talk Radio Show hosted by Andrew Schorr, 2007.
8. The University of Texas M.D. Anderson Website. Video - Focus on Prostate Cancer, 2010.
9. The University of Texas M.D. Anderson Website. Radiation Treatment for Prostate Cancer. Patient Power, Weekly web-based talk radio show hosted by Andrew Schorr, 2010.

Grant & Contract Support

Title: Comparative Effectiveness of Treatments for Localized Prostate Cancer
Funding Source: Recovery Act 2009 AHRQ Choice Grant
Role: Co-Investigator
Principal Investigator: Penson D
Duration: 8/1/2011 - 7/1/2013
 
Title: Acceptability of Active Surveillance as a Treatment Choice for Prostate Cancer among U.S. Men
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Volk, R
Duration: 9/1/2009 - 9/1/2012
 
Title: R-Clinical Decisions and Communication Sciences (The John M. Eisenberg Center for Clinical Decisions and Communications Science)
Funding Source: Agency for Healthcare Research and Quality
Role: Consultant/Medical Content Expert
Principal Investigator: Volk R
Duration: 9/25/2008 - 10/5/2013
 
Title: Efficacy of Cancer Support Group Programs: A Social Comparison Theory Analysis.
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Carmack-Taylor, C
Duration: 7/1/2008 - 6/30/2010
 
Title: A Comprehensive, Multimodality Quality of Life Study for Prostate Cancer
Funding Source: UTMDACC Prostate Cancer Research Program
Role: Principal Investigator
Duration: 1/1/2008 - 12/1/2012
 
Title: Evaluating the role of genetic makers in prostate cancer progression
Funding Source: Department of Defense (DOD)
Role: Co-Investigator
Principal Investigator: Strom S
Duration: 9/4/2007 - 10/3/2010
 
Title: Real-time in vivo Dosimetry in Radiation Therapy using Scintillation Detectors
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Beddar, S
Duration: 7/1/2007 - 5/31/2010
 
Title: Optimizing the Delivery of Lifestyle Interventions in Cancer Survivors
Funding Source: U.T.M.D. Anderson Multidisciplinary Research Program
Role: Co-Investigator
Principal Investigator: Demark-Wahnefried, W Basen-Engquist, K

Last updated: 8/7/2015